Expanding access to biotherapeutics in low-income and middle-income countries through public health non-exclusive voluntary intellectual property licensing: considerations, requirements, and opportunities-Reference-Cited by-同舟云学术

Expanding access to biotherapeutics in low-income and middle-income countries through public health non-exclusive voluntary intellectual property licensing: considerations, requirements, and opportunities

Published:2023-01 Issue:1 Volume:11 Page:e145-e154
ISSN:2214-109X
Container-title:The Lancet Global Health
language:en
Short-container-title:The Lancet Global Health

Author:

Morin Sébastien,Segafredo Giulia,Piccolis Manuele,Das Aditi,Das Meghmala,Loffredi Nicola,Larbi Amina,Mwamelo Kim,Villanueva Elena,Nobre Sandra,Burrone Esteban

Publisher

Elsevier BV

Subject

General Medicine

Reference44 articles.

1. The characteristics of patents impacting availability of biosimilars;Van de Wiele;Nat Biotechnol,2022

2. Affordability of cancer drugs in sub-Saharan Africa: effects of pricing on needless loss of life;Martei;JAMA Oncol,2017

3. Access to high-cost drugs for advanced breast cancer in Latin America, particularly trastuzumab;Barrios;Ecancermedicalscience,2019

4. The global landscape of availability, accessibility and affordability of essential diagnostics and therapeutics for the management of HER2-positive breast cancer: the ONCOLLEGE-001 survey;Trapani;J Cancer Policy,2021

5. Biosimilars for the management of rheumatoid arthritis: economic considerations;Gulácsi;Expert Rev Clin Immunol,2015

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Access to highly effective long-acting RSV-monoclonal antibodies for children in LMICs—reducing global inequity;The Lancet Global Health;2024-07

2. Novel approaches to enable equitable access to monoclonal antibodies in low- and middle-income countries;PLOS Global Public Health;2024-07-01

3. Geographical and sociodemographic epidemiology of inflammatory bowel disease in young females from 2010 to 2019;Digestive and Liver Disease;2024-07

4. Global outlook on affordability of biotherapeutic drugs;Annals of the New York Academy of Sciences;2024-06-13

5. Monoclonal antibody biosimilars for cancer treatment;iScience;2024-06